Webinar: Syphilis Outbreak in the Indigenous Community

SHINE SA, posted May 14, 2020

This free education session is presented by Adelaide Sexual Health Centre and will provide an update on syphilis.

General practitioners, nurses and/or midwives, Aboriginal Health Practitioners and Aboriginal Health Workers are encouraged to register for this training.

COURSE DETAILS

Date: 16 June 2020
Time: 7:00pm – 9:00pm

The webinar will cover:

  • Update on epidemiology
  • Review of diagnosis, staging and management of syphilis cases
  • How to interpret syphilis serology
  • Syphilis in pregnancy
  • Approaches to Partner Notification
  • Introduction to the South Australian Syphilis Register

Presenters:
Dr Alison Ward, Senior Consultant Sexual Health Physician
Njirrah Rowe, Aboriginal STI Education Coordinator and Partner Notification Officer

This activity is pending RACGP approval for 4 CPD activity points

This session is part of the Syphilis Outbreak Response and is a partnership between SHINE SA and Adelaide Sexual Health Centre.

No cost to attend.

Australian Health Organisations refute Cochrane Review Report and affirm efficacy of DAA therapy for hepatitis C

Joint position statement, Australia, June 2017

This joint Position Statement aims to strongly refute and reject the findings of the Cochrane Review report titled Direct-acting antivirals for chronic hepatitis C, published by the Cochrane Hepato‐Biliary Group on 6 June 2017.

The Position Statement was prepared by the expert panel who published a Consensus Statement for Australian recommendations for the management of hepatitis C for virus infection representing the Gastroenterological Society of Australia (Australian Liver Association), the Australasian Society for Infectious Diseases, the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine, the Australasian Hepatology Association, Hepatitis Australia and the Royal Australian College of General Practitioners.

The organisations above developed this position statement to urge health practitioners and patients not to be swayed by this flawed report claiming new direct-acting antivirals (DAAs) for hepatitis C do not save lives.